Name (Synonyms) | Correlation | |
---|---|---|
drug1559 | Lenzilumab Wiki | 1.00 |
drug3498 | tocilizumab Wiki | 0.71 |
drug2698 | Standard of Care Wiki | 0.18 |
drug2122 | Placebo Wiki | 0.05 |
There is one clinical trial.
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.
Description: This outcome is defined by a composite 1 year post-transplant endpoint of: detection of de novo donor-specific antibodies (dnDSA) (Core Laboratory), acute cellular rejection (ACR) ≥ ISHLT 2R rejection (Core Laboratory), antibody mediated rejection (AMR) ≥ ISHLT AMR 1 (Core Laboratory), hemodynamic compromise rejection in the absence of a biopsy or histological rejection, death, or re-transplantation.
Measure: Proportion of Participants Positive for Event of dnDSA, ACR, AMR, Hemodynamic Compromise, Death or Re-Transplantation - By Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of de novo donor-specific antibodies (dnDSA). dnDSA is a newly developed alloantibody that is against the donor organ.
Measure: Freedom of Detection of de Novo Donor-Specific Antibodies (dnDSA) - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of acute cellular rejection ≥2R (Reference: International Society of Heart and Lung Transplantation [ISHLT] acute cellular rejection-grade 2R or greater severity).
Measure: Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of antibody-mediated rejection defined as ISHLT grade AMR 1 or greater severity.
Measure: Freedom from Antibody Mediated Rejection (AMR) ≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1 - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of hemodynamic compromise (HDC). Hemodynamic compromise is defined by: - Need for inotropic agents due to a Cardiac Index (CI) <2.0 L/min/m^2 or a 25% decrease from baseline, in addition to one of the following: ejection fraction of <40% or a 20% decrease from baseline, and the need for inotropic agents OR fractional shortening of <20% or a 25% decrease from baseline, and the need for inotropic agents.
Measure: Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of episode of rejection requiring treatment. Reference: Acute cellular rejection as defined by the 2004 International Society of Heart and Lung Transplantation (ISHLT) grading scale.
Measure: Freedom from Any-Treated Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from acute cellular rejection (ACR) ≥ ISHLT 2R rejection. Reference: 2004 International Society of Heart and Lung Transplantation [ISHLT [ grading scale).
Measure: Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Per Patient - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups. Hemodynamic compromise is defined as the need for inotropic agents due to a Cardiac Index (CI) <2.0 L/min/m2 or a 25% decrease from baseline in addition to one of the following: Ejection fraction of <40% or a 20% decrease from baseline, and the need for inotropic agents Fractional shortening of <20% or a 25% decrease from baseline, and the need for inotropic agents
Measure: Freedom from Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups
Measure: Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of all-cause mortality will be compared between the treatment groups.
Measure: Occurrence of Death - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of participant(s) being re-listed for transplant will be compared between the treatment groups.
Measure: Occurrence of Re-Listed for Transplantation - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of participant(s) re-transplantation will be compared between the treatment groups.
Measure: Occurrence of Re-Transplantation - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: The frequency of events will be compared between the treatment groups.
Measure: Number of Acute Cellular Rejection (≥ International Society of Heart and Lung Transplantation (ISHLT) 2R) Per Patient - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: The frequency of events will be compared between the treatment groups.
Measure: Number of Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group Time: 12 months post-transplantationDescription: The frequency of events will be compared between the treatment groups.
Measure: Number of Rejection Episodes Associated with Hemodynamic Compromise (HDC) Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: Per protocol, per clinical research site standard of care.
Measure: Change in Intravascular Ultrasound (IVUS) Measurements From Baseline to 1 Year Post-Transplant- by Treatment Group Time: Baseline (4 to 8 weeks post-transplant), 1 year post-transplantDescription: In accordance with the International Society of Heart and Lung Transplantation (ISHLT) Cardiac Allograft Vasculopathy (CAV) angiographic grading scale.
Measure: Angiographic Evidence of Cardiac Allograft Vasculopathy (CAV) - by Treatment Group Time: 12 months post-transplantationDescription: Incidence of participant loss to follow up will be compared between the treatment groups.
Measure: Participant Loss to follow up - by Treatment Group Time: 12 months post-transplantationDescription: The frequency of serious infections requiring intravenous antimicrobial therapy and need for hospitalization will be compared between treatment groups.
Measure: Occurrence of Serious Infections Requiring Intravenous Antimicrobial Therapy and Need for Hospitalization - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of tuberculosis will be compared between treatment groups.
Measure: Incidence of Tuberculosis - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of CMV infection will be compared between treatment groups.
Measure: Incidence of Cytomegalovirus (CMV) Infection - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of PTLD will be compared between treatment groups.
Measure: Incidence of Post-Transplant Lymphoproliferative Disease (PTLD) - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The number of participants who discontinue study drug, per protocol, will be compared between treatment groups.
Measure: Tolerability (Discontinuation of Study Drug) of Tocilizumab (TCZ) - by Treatment Group Time: Through 24 months post transplant surgery